BioSpace News Archive

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Monday, August 14, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the second quarter of 2023.

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Executive Officer Dr. Matt Coffey will participate in a fireside chat at Canaccord Genuity’s 43rd Annual Growth Conference, which is taking place August 7-10, 2023 at the InterContinental Boston in Boston, MA.

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on July 31, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 1950 shares of its common stock to one new employee.

BridgeBio Pharma, Inc. today announced that on August 02, 2023, the compensation committee of BridgeBio’s board of directors granted seven new employees restricted stock units for an aggregate of 26,657 shares of the Company’s common stock.

Fulgent Genetics, Inc. today announced financial results for its second quarter ended June 30, 2023.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2023 ended June 30, 2023.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Bioventus Inc. will present at the Canaccord Genuity Global Growth Conference on Thursday, August 10, 2023, at 8:00 a.m. ET.

Saluda Medical, Inc. announced the publication of new health economic data in The Clinical Journal of Pain that provides the strongest ever economic case for the use of Evoke® Closed-Loop SCS with physiologic SmartLoop™ technology over open-loop SCS therapy.

INVO Bioscience, Inc. announced the pricing of its public offering of 1,580,000 units, with each unit consisting of one share of common stock and two warrants, each to purchase one share of common stock.